Clinical Significance of αvβ3 Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions

Several lines of experimental evidence in in vitro and animal model systems suggest that the integrin αvβ3 plays a role in the tumorigenicity of human melanoma cells and that the blocking of αvβ3 ligand binding can inhibit tumor progression. However, there is only scanty information about the role of αvβ3 in malignant melanoma in a clinical setting. Therefore, in the present study, we have analyzed the distribution in lesions of melanocyte origin and in normal tissues of the αv integrin subunit and of the αvβ3 complex and their association with histopathological and clinical parameters of malignant melanoma. We have used as probes the monoclonal antibodies (mAbs) TP36.1 and VF27.263.15, which we have shown with a combination of serological and immunochemical assays to be specific for the αv subunit and for the αvβ3 complex, respectively. In immunohistochemical assays, mAb TP36.1 stained both benign and malignant lesions of melanocyte origin. In contrast, the reactivity of mAb VF27.263.15 was restricted to malignant lesions. Both mAbs displayed differential reactivity with primary melanoma lesions of different histotypes because they stained about 50% of acral lentiginous melanoma and superficial spreading melanoma lesions, at least 80% of nodular melanoma lesions, and none of the uveal melanoma lesions tested. Both mAbs TP36.1 and VF27.263.15 stained about 60% of lymph node metastases and 80% of cutaneous metastases. Expression of the αvβ3 complex in melanocytic lesions resembles that of intercellular adhesion molecule-1 (ICAM-1) in several respects: ( a ) both are expressed in a significantly ( P < 0.004) larger proportion of malignant than of benign lesions; ( b ) expression of both molecules in primary melanoma lesions is significantly ( P < 0.05) associated with lesion thickness; and ( c ) expression of both molecules in primary lesions from patients with stage I melanoma is significantly ( P < 0.05) associated with an increased probability of disease recurrence following surgical excision. αvβ3 and ICAM-1 in primary melanoma lesions complement each other in predicting the outcome of the disease, because the association with prognosis was enhanced when primary lesions were stained by both anti-αvβ3 mAb VF27.263.15 and anti-ICAM-1 mAb CL203.4 or by neither mAb. Because αvβ3 has been suggested as a potential target of immunotherapy, its distribution in normal tissues was investigated. αvβ3 expression is restricted because it was only detected in ductal epithelium of parotid glands, thyrocytes, basal glands of the stomach, colonic and rectal epithelium glomeruli, Bowman's capsules and proximal and distal tubules of kidneys, and endometrial epithelium. These findings suggest that renal function will be a critical clinical parameter to monitor in therapies of malignant diseases relying on systemic administration of anti-αvβ3 mAb.

[1]  E. Danen,et al.  Emergence of α5β1 fibronectin‐ and αvβ3 vitronectin‐receptor expression in melanocytic tumour progression , 1994 .

[2]  W. Bonner,et al.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. , 1974, European journal of biochemistry.

[3]  D. Elder,et al.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.

[4]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.

[5]  D. Cheresh,et al.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. , 1992, The Journal of clinical investigation.

[6]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[7]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[8]  E. Bröcker,et al.  The eortc melanoma group exchange program: Evaluation of a multicenter monoclonal antibody study , 1991, International journal of cancer.

[9]  S. Ferrone,et al.  Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. , 1987, Journal of immunology.

[10]  D. Cheresh,et al.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. , 1987, The Journal of biological chemistry.

[11]  A. Breslow Tumor Thickness, Level of Invasion and Node Dissection in Stage I Cutaneous Melanoma , 1975, Annals of surgery.

[12]  J. Johnson,et al.  De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Wayner,et al.  Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface , 1991, The Journal of cell biology.

[14]  G. Duigou,et al.  Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. , 1989, Cancer research.

[15]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[16]  Zaverio M. Ruggeri,et al.  Role of 3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow (*) , 1996, The Journal of Biological Chemistry.

[17]  J W Smith,et al.  The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. , 1988, The Journal of biological chemistry.

[18]  E. Danen,et al.  Integrin expression in uveal melanoma differs from cutaneous melanoma. , 1993, Investigative ophthalmology & visual science.

[19]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[20]  D. Phillips,et al.  A method for purifying the platelet membrane glycoprotein IIb-IIIa complex. , 1985, Analytical biochemistry.

[21]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[22]  S. Ferrone,et al.  A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. , 1982, Journal of the National Cancer Institute.

[23]  E. Ruoslahti,et al.  Association of insulin receptor substrate-1 with integrins. , 1994, Science.

[24]  W. Clark,et al.  The developmental biology of primary human malignant melanomas. , 1975, Seminars in oncology.

[25]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[26]  J. Koziol,et al.  Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. , 1987, Blood.

[27]  M. Nakajima,et al.  The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762nf mammary adenocarcinoma cells , 1988, International journal of cancer.

[28]  E. Shevach,et al.  Production and properties of monoclonal antibodies to guinea pig Ia antigens. , 1983, Methods in enzymology.

[29]  D. Cheresh,et al.  Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Ferrone,et al.  Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. , 1989, Hybridoma.

[31]  S. Ferrone,et al.  Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. , 1993, Cancer research.

[32]  M. Maio,et al.  Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. , 1993, Cancer research.